

Section 6.

Systemic Anti-Cancer Therapies (SACT)

Section 6. Systemic Anti-Cancer Therapies (SACT)

| <p>6.0 Cancer treatment, patient and occupational safety in relation to SACT Understanding the safe delivery and management of SACT to treat CYP cancer, with appropriate assessment and care during treatment. Providing relevant and timely information to enable CYP, families and carers to engage in clinical decision-making about their treatment and care. N.B. These competencies facilitate SACT sign-off and are intended to work alongside the SACT Passport</p> | <p>Pre and post-registration nurses providing generalist CYP cancer care (e.g. A&E, PICU, Practice nurses, general wards, radiology departments)</p> | | <p>Unregistered Support Workers in specialist CYP cancer</p> | <p>Registrants providing specialist CYP cancer care (PTC and designated cancer specialist roles in POSCUs)</p> | | | | |
|--|---|--------------------------------|---|---|--------------------------|------------------------|------------------------|--------------------------|
| <p>Learning outcomes: Practitioners will be able to:</p> | <p>Pre-reg Children's Field</p> | <p>Registered Nurse</p> | <p>Health Care Assistant / support worker</p> | <p>Nursing Associate</p> | <p>Registered</p> | <p>Enhanced</p> | <p>Advanced</p> | <p>Consultant</p> |
| 6.1 Describe the difference between local and systemic cancer treatments and demonstrate understanding of the different treatment modalities | | | | | | | | |
| 6.2 Identify SACT agents used for CYP treatments and routes of administration | | | | | | | | |
| 6.3 Identify differences between biological agents and SACT agents | | | | | | | | |
| 6.4 Understand that SACT can only be prescribed by registered prescribers and administered by staff trained to administer. Can identify how to find this information | | | | | | | | |
| 6.5 Identify drug compatibilities when giving multi drug schedules in relation to adjuvant therapy e.g. fluids and supportive therapies | | | | | | | | |
| 6.6 Display knowledge and understanding of the correct personal protective equipment (PPE) required to maintain own safety whilst handling SACT or waste products | | | | | | | | |
| 6.7 Understand and explain the procedure for dealing with contaminated skin / eyes | | | | | | | | |
| 6.8 Discuss the role of Occupational Health in relation to SACT (PPE, contamination and guidance for pregnant staff) | | | | | | | | |
| 6.9 Describe and demonstrate how SACT is delivered safely and effectively including own responsibilities in the administration of SACT according to role | | | | | | | | |
| 6.10 Explain the range of support required and available to CYP, families and carers throughout treatment | | | | | | | | |
| 6.11 Evidence that all knowledge sections of the UKONS / CCLG SACT Passport (relevant to role) have been successfully completed | | | | | | | | |
| <p>Practice competencies: Practitioners will be able to:</p> | <p>Pre-reg Children's Field</p> | <p>Registered Nurse</p> | <p>Health Care Assistant / support worker</p> | <p>Nursing Associate</p> | <p>Registered</p> | <p>Enhanced</p> | <p>Advanced</p> | <p>Consultant</p> |
| <p>CYP, families and carers Information, Education and Support (See also section 4.)</p> | | | | | | | | |
| 6.12 Provide information in a range of formats and explain to CYP, families and carers at an age, developmentally appropriate level and pace, the range of SACT available to facilitate involvement in clinical decision-making about their treatment, care and management | | | | | | | | |

Section 6 continued ▼

Section 6. Systemic Anti-Cancer Therapies (SACT)

| | | | | | | | | | |
|------------------------------------|---|--|--|--|--|--|--|--|--|
| 6.13 | Ensure CYP (when age appropriate), family and carers have written information which should include; <ul style="list-style-type: none"> • Individualised treatment plan / regime • Chemotherapy / SACT Alert Card • Chemo diary or patient held journal (if used locally) • Advice line number (in and out-of-hours) • Next appointment with healthcare professional | | | | | | | | |
| 6.14 | Provide a supportive environment in which CYP, families and carers are encouraged to ask questions and share their concerns about their disease and treatment | | | | | | | | |
| 6.15 | Advocate or act in best interests to promote CYP, families and carers involvement in decision-making about SACT | | | | | | | | |
| 6.16 | Give clear explanations to CYP, families and carers about the SACT being administered | | | | | | | | |
| 6.17 | Identify the appropriate support required and demonstrate awareness of where to find the support to reduce anxiety, increase understanding and encourage concordance | | | | | | | | |
| 6.18 | Give clear explanations to CYP, families and carers about the precautions to take when handling excreta or items contaminated by excreta in hospital and at home | | | | | | | | |
| Prescriptions and Protocols | | | | | | | | | |
| 6.19 | Complete pre-administration preparation; review treatment order, availability of prescribed and dispensed SACT agents, availability of equipment required, locate protocol and prescription | | | | | | | | |
| 6.20 | Assist locating equipment to be used and routine decontamination | | | | | | | | |
| 6.21 | Verify any relevant pre SACT investigations have been completed before treatment commences, check SACT prescription against protocol | | | | | | | | |
| 6.22 | Identify any pre-medications or pre-hydration and ensure it has been administered | | | | | | | | |
| 6.23 | Identify need and patient preferences for topical anaesthetics / ice / buzzy devices to manage pain prior to SACT via subcutaneous, intramuscular or cannulation routes, including in preparation health play specialists when required | | | | | | | | |
| 6.24 | Locate information about SACT products, side effects and contra-indications | | | | | | | | |
| 6.25 | Able to interpret clinical tests and is aware of normal blood parameters and required levels for treatment | | | | | | | | |
| 6.26 | Ensure that all medicines have been stored correctly (all nurses in storage and supply chain) , and the product integrity is intact before administration (SACT administrators only). | | | | | | | | |
| 6.27 | Lead and make autonomous clinical decisions where appropriate in the assessment, prescribing, management and monitoring of SACT (See https://www.cclg.org.uk/ACP-capabilities V1.0 pp. 17-18 for detailed breakdown) | | | | | | | | |
| 6.28 | Lead and make autonomous decisions where appropriate, in supporting SACT for CYP undergoing Haematopoietic Stem Cell Transplant (HSCT) (See https://www.cclg.org.uk/ACP-capabilities V1.0 pp.20-23 for detailed breakdown) | | | | | | | | |

Section 6. Systemic Anti-Cancer Therapies (SACT)

| Administration of SACT (Applicable to level of involvement by role) | | | | | | | | |
|---|--|--|--|--|--|--|--|--|
| 6.29 | Correctly identify the patient and review their understanding, perceptions, previous experiences, and toxicity history | | | | | | | |
| 6.30 | Deliver high standard of hand-hygiene and Aseptic Non-Touch Technique (ANTT) as per local policy; remaining mindful of vulnerable immunocompromised patient group | | | | | | | |
| 6.31 | Ensure patients ability to take oral medications correctly, offering guidance and helpful techniques to patient, family and carers | | | | | | | |
| 6.32 | Ensure patent venous access for intravenous SACT administration routes | | | | | | | |
| 6.33 | Administer SACT following drug administration policies, medicines management policies and administration guidance in the protocol | | | | | | | |
| 6.34 | Sets infusion rates, pressures and other relevant parameters as per prescription, necessary calculations, and equipment guidelines | | | | | | | |
| Personal Protective Equipment and Safe Handling | | | | | | | | |
| 6.35 | Recognise the hazards associated with SACT and take preventative actions to minimise these to comply with local and national safety regulations, COSHH regulations, legislation and guidelines for storage, transportation, safe handling, spillage and disposal | | | | | | | |
| 6.36 | Handle SACT and / or associated equipment safely and reduce the potential for spillage | | | | | | | |
| 6.37 | Check patency of access during bolus or infusion SACT intermittently (local policy) and intervene appropriately if complications or reaction become evident | | | | | | | |
| Waste and spillage | | | | | | | | |
| 6.38 | Dispose of excreta according to local policy | | | | | | | |
| 6.39 | Explain and execute the action to be taken in the event of a spillage, including the equipment required and identify their location | | | | | | | |
| 6.40 | Explain and execute the procedure for dealing with contaminated linen and equipment | | | | | | | |
| 6.41 | Ensure appropriate safety equipment is accessible: cytotoxic extravasation kit, spillage kit, sharps and waste disposal containers | | | | | | | |
| Professional Responsibilities | | | | | | | | |
| 6.42 | Know when to refer to and involve other healthcare providers and recognise situations where more senior support is needed | | | | | | | |
| 6.43 | Document episode of care with accurate, complete and transparent record keeping conforming with NMC and local guidelines for record keeping | | | | | | | |
| 6.44 | Provide information and support to, and act as a role model for colleagues to ensure safe practice in the treatment settings | | | | | | | |
| 6.45 | Utilise appropriate policies associated with SACT | | | | | | | |
| 6.46 | Ensure appropriate methods of communication are utilised to communicate necessary information from SACT care episode to MDT and other relevant healthcare professionals | | | | | | | |

Section 6. Systemic Anti-Cancer Therapies (SACT)

| | | | | | | | | |
|---|--|--|--|--|--|--|--|--|
| 6.47 Ensure patient is aware when the therapeutic interaction is complete and has adequate follow-up arrangements and discharge medications if required | | | | | | | | |
| 6.48 Evidence that 5 practical assessments have been completed in line with UKONS / CCLG SACT Passport | | | | | | | | |

Section 6b. Systemic Anti-Cancer Therapies Safety Work Based Record Sheet

| <p>6.0 Cancer treatment, patient and occupational safety in relation to SACT: Understanding the safe delivery and management of SACT to treat CYP cancer, with appropriate assessment and care during treatment. Providing relevant and timely information to enable CYP, families and carers to engage in clinical decision-making about their treatment and care.</p> <p>N.B. These competencies facilitate SACT sign-off and are intended to work alongside the SACT Passport</p> | Practitioner Level (See Key) | | | | | | | Level of Achievement Required (Benner Taxonomy) | Self Assessment | Level Achieved (Assessed) | | | Evidence of Achievement |
|---|---------------------------------|---|--|--|--|--|--|--|-----------------|------------------------------|----------|-------|---|
| Learning outcomes: Practitioners will be able to: | | | | | | | | | | L | Date | Sig. | |
| <p>EXAMPLE</p> <p>6.4 Understand that SACT can only be prescribed by registered prescribers and administered by staff trained to administer. Can identify how to find this information.</p> | | ✓ | | | | | | Competent | Competent | P | 28.05.22 | J Doe | <ul style="list-style-type: none"> Discussed own role in POSCU with supervisor. Aware that only the chemo trained staff can administer SACT Can locate policies relating to SACT for handling excreted waste, as per 6.25-6.29 |
| 6.1 Describe the difference between local and systemic cancer treatments and demonstrate understanding of the different treatment modalities | | | | | | | | | | | | | |
| 6.2 Identify SACT agents used for CYP treatments and routes of administration | | | | | | | | | | | | | |
| 6.3 Identify differences between biological agents and SACT agents | | | | | | | | | | | | | |
| 6.4 Understand that SACT can only be prescribed by registered prescribers and administered by staff trained to administer. Can identify how to find this information | | | | | | | | | | | | | |
| 6.5 Identify drug compatibilities when giving multi drug schedules in relation to adjuvant therapy e.g. fluids and supportive therapies | | | | | | | | | | | | | |
| 6.6 Display knowledge and understanding of the correct personal protective equipment (PPE) required to maintain own safety whilst handling SACT or waste products | | | | | | | | | | | | | |
| 6.7 Understand and explain the procedure for dealing with contaminated skin / eyes | | | | | | | | | | | | | |

Section 6b. Systemic Anti-Cancer Therapies Safety Work Based Record Sheet

| | | | | | | | | | | | | | | | |
|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| 6.8 Discuss the role of Occupational Health in relation to SACT (PPE, contamination and guidance for pregnant staff) | | | | | | | | | | | | | | | |
| 6.9 Describe and demonstrate how SACT is delivered safely and effectively including own responsibilities in the administration of SACT according to role | | | | | | | | | | | | | | | |
| 6.10 Explain the range of support required and available to CYP, families and carers throughout treatment | | | | | | | | | | | | | | | |
| 6.11 Evidence that all knowledge sections of the UKONS / CCLG SACT Passport (relevant to role) have been successfully completed | | | | | | | | | | | | | | | |
| Practice competencies: Practitioners will be able to: | | | | | | | | | | | | | | | |
| CYP, families and carers Information, Education and Support (See also section 4.) | | | | | | | | | | | | | | | |
| 6.12 Provide information in a range of formats and explain to CYP, families and carers at an age, developmentally appropriate level and pace, the range of SACT available to facilitate involvement in clinical decision-making about their treatment, care and management | | | | | | | | | | | | | | | |
| 6.13 Ensure CYP (when age appropriate), family and carers have written information which should include; <ul style="list-style-type: none"> • Individualised treatment plan / regime • Chemotherapy / SACT Alert Card • Chemo diary or patient held journal (if used locally) • Advice line number (in and out-of-hours) • Next appointment with healthcare professional | | | | | | | | | | | | | | | |
| 6.14 Provide a supportive environment in which CYP, families and carers are encouraged to ask questions and share their concerns about their disease and treatment | | | | | | | | | | | | | | | |
| 6.15 Advocate or act in best interests to promote CYP, families and carers involvement in decision-making about SACT | | | | | | | | | | | | | | | |
| 6.16 Give clear explanations to CYP, families and carers about the SACT being administered | | | | | | | | | | | | | | | |

Section 6b. Systemic Anti-Cancer Therapies Safety Work Based Record Sheet

| | | | | | | | | | | | | | | | |
|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| 6.17 Apply the same high standards of observation and record keeping for CYP following standard or individualised guidelines, as for those taking part in clinical trials | | | | | | | | | | | | | | | |
| 6.18 Give clear explanations to CYP, families and carers about the precautions to take when handling excreta or items contaminated by excreta in hospital and at home | | | | | | | | | | | | | | | |
| Prescription and Protocols | | | | | | | | | | | | | | | |
| 6.19 Complete pre-administration preparation; review treatment order, availability of prescribed and dispensed SACT agents, availability of equipment required, locate protocol and prescription | | | | | | | | | | | | | | | |
| 6.20 Assist locating equipment to be used and routine decontamination | | | | | | | | | | | | | | | |
| 6.21 Verify any relevant pre SACT investigations have been completed before treatment commences, check SACT prescription against protocol | | | | | | | | | | | | | | | |
| 6.22 Identify any pre-medications or pre-hydration and ensure it has been administered | | | | | | | | | | | | | | | |
| 6.23 Identify need and patient preferences for topical anaesthetics / ice / buzzy devices to manage pain prior to SACT via subcutaneous, intramuscular or cannulation routes, including in preparation health play specialists when required | | | | | | | | | | | | | | | |
| 6.24 Locate information about SACT products, side effects and contra-indications | | | | | | | | | | | | | | | |
| 6.25 Able to interpret clinical tests and is aware of normal blood parameters and required levels for treatment | | | | | | | | | | | | | | | |
| 6.26 Ensure that all medicines have been stored correctly (all nurses in storage and supply chain) , and the product integrity is intact before administration (SACT administrators only) | | | | | | | | | | | | | | | |

Section 6b. Systemic Anti-Cancer Therapies Safety Work Based Record Sheet

| | | | | | | | | | | | | | | | |
|--|-----------|--|--|--|--|--|--|--|--|--|--|-------|--|--|--|
| 6.46 Ensure appropriate methods of communication are utilised to communicate necessary information from SACT care episode to MDT and other relevant healthcare professionals | | | | | | | | | | | | | | | |
| 6.47 Ensure patient is aware when the therapeutic interaction is complete and has adequate follow-up arrangements and discharge medications if required | | | | | | | | | | | | | | | |
| 6.48 Evidence that 5 practical assessments have been completed in line with UKONS / CCLG SACT Passport | | | | | | | | | | | | | | | |
| Action plan to achieve required competency level: | | | | | | | | | | | | | | | |
| Reviewed by | Comments: | | | | | | | | | | | | | | |
| Signature and Role: | | | | | | | | | | | | Date: | | | |
| Signature and Role: | | | | | | | | | | | | Date: | | | |
| Signature and Role: | | | | | | | | | | | | Date: | | | |